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Abstract 
BACGROUND Depression is common in people with Alzheimer’s disease (AD) affecting 
overall outcomes and decreasing quality of life. Although depression in AD is primarily treated 
with antidepressants, there are few randomised controlled trials (RCTs) assessing efficacy and 
results have been conflicting.   
OBJECTIVES To systematically review evidence on efficacy of antidepressant treatments for 
depression in AD.    
METHODS Systematic review and meta-analysis of double blind RCTs comparing 
antidepressants v. placebo for depression in AD. We searched MEDLINE, CINAHL, EMBASE, 
PsycINFO, the Cochrane Controlled Trials Register and on line national and international 
registers. Primary outcomes were treatment response and depressive symptoms. Secondary 
outcomes were cognition, acceptability and tolerability. Risk of bias was also assessed.       
RESULTS Seven studies met inclusion criteria. Three compared sertraline with placebo; one 
compared both sertraline and mirtazapine to placebo; imipramine, fluoxetine and clomipramine 
were evaluated in one study each. In terms of response to treatment (6 studies, 297 patients 
treated with antidepressants and 223 with placebo), no statistically significant difference between 
antidepressants and placebo was found (odds ratio (OR) 1.95, 95% CI 0.97-3.92). We found no 
significant drug-placebo difference for depressive symptoms (5 studies, 311 patients, SMD -
0.13; 95% CI -0.49 to 0.24). Overall quality of the evidence was moderate because of 
methodological limitations in studies and the small number of trials. 
CONCLUSION Despite the importance of depression in people with AD, few RCTs are 
available on efficacy of antidepressants, limiting clear conclusions of their potential role. There 
is a need for further high quality RCTs.   
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Introduction 
     Alzheimer’s disease (AD) is a primary neurodegenerative dementia and is one of the leading 
causes of disability in older people [1,2]. While progressive cognitive impairment is the hallmark 
of the illness, neuropsychiatric symptoms affect almost all patients and are persistent [3,4]. 
Depression is one of the most common neuropsychiatric symptoms in AD, associated with 
institutionalisation [5], and mortality [6,7]. Up to 50% of AD patients experience depression or 
clinically significant depressive symptoms during the course of the disease [8]. Major depressive 
disorder affects approximately 20% to 30% of people with AD [9,10], and personal or family 
history of depression [11], and younger age at onset of dementia are risk factors [12]. Depressive 
symptoms are more common than clinical depression [13,14], and are highly persistent [10]. 
Depression and depressive symptoms increase the risk of behavioural disturbance and accelerate 
functional decline [15].   
     Antidepressants remain the mainstay of treatment for AD patients with depression. This is 
driven by a lack of alternative treatment options and a perception that antidepressants are 
effective in this population [16]. In line with a recent clinical review of the literature [17], there 
does not appear to be clear evidence from systematic reviews and meta-analyses to support this 
practice. Several randomised controlled trials (RCTs) testing antidepressants versus placebo have 
produced conflicting results [18-22]. In an antidepressants withdrawal study, patients with 
neuropsychiatric symptoms showed a worsening of depressive symptoms compared to those who 
continued treatment [23].   
     There is conflicting evidence on the effects of antidepressants on cognition, with some studies 
reporting a beneficial effect [24-26] and some harmful [27]. Psychological therapies have also 
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been studied for depression in AD, with a systematic review reporting that current evidence is 
limited due to the small number of trials and varying approaches used [28].  
     Use of antidepressants in AD is associated with significant side-effects including 
hyponatraemia [29], cardiotoxicity [30] and increased bleeding tendency [27,31,32].      
Effectiveness of antidepressants in AD has been evaluated by narrative reviews [33], whereas 
quantitative reviews and meta-analyses have examined effectiveness in all types of dementia but 
have not included latest studies conducted [34,35]. In this review, we investigated efficacy and 
acceptability by conducting a comprehensive, recent, worldwide review of the literature of 
antidepressants for depression in AD.  
Methods 
     We searched major health databases such as MEDLINE, EMBASE, CINHAL, PsycINFO and 
the Cochrane library for ongoing trials, as well as national and international trial registers, to 
March 2016. We searched for all depression AD RCTs with additional search terms (including 
each antidepressant as a separate term, see Appendix 1 for the full search strategy). We scanned 
the reference lists of all included studies and 82 reviews in the area of depression in AD and 
other dementias.  
     Inclusion criteria were: (1) RCTs comparing any single antidepressants with placebo, (2) 
people with a diagnosis of AD, (3) patients with a diagnosis of depression as confirmed by either 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria [36] or either disease-
specific criteria [14] or a validated rating scale for depression in older people. Validated scales 
included those used in both clinical and research settings in old age psychiatry [37], such as the 
Hamilton Depression Rating Scale (HDRS/HAM-D) [38], the Montgomery Asberg Depression 
Rating Scale (MADRS) [39], and the Cornell Scale for Depression in Dementia [40].   
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     There were no restrictions in terms of participant characteristics, or class of antidepressants 
and studies in minor depression in Alzheimer’s disease were considered eligible. Studies that 
compared 2 treatment groups with placebo were included as long as there were separate results 
reported on the effects of each of the antidepressants. Primary outcomes were response to 
treatment and mean depression scores between the treatment and placebo groups. Secondary 
outcomes were cognition, number of drop-outs, and number of adverse events. We used a 
random-effects model to represent overall estimate effects, and where appropriate, used 
standardised mean differences as not all studies used the same outcome measures of depression. 
Heterogeneity was assessed with the chi-squared test.                   
     Two reviewers independently extracted data (VO, RN), and any disagreements were resolved 
with a third author (NT). We used Revman 5.3.5. for data analysis, and the Risk of Bias Tool as 
recommended by the Cochrane Handbook to assess risk of bias in the included studies, which 
was assessed independently (VO, RN) (on domains of sequence generation, allocation 
concealment, blinding, incomplete outcome data, and selective reporting). Disagreement on 
quality of studies was low and was resolved by authors’ consensus. We used the GRADE 
approach [41] to summarise overall quality of evidence.  We identified a total of 3808 references 
through database searching and 13 additional references via other sources (reference lists of 
identified studies and reviews of the literature). After removal of duplicates and clearly irrelevant 
articles we retrieved 148 full text records. Irrelevant articles were those that were not directly 
relevant to the study of effectiveness of antidepressants in depression in older people with 
cognitive impairment and/or dementia. Of the 148 full text records, we excluded 109 as not 
relevant, leaving 38 full text references to be fully assessed for eligibility. A further 27 were 
excluded as not meeting criteria of this review (see Appendix Table 1 for details). We identified 
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one ongoing study [42] (DIADs-3) investigating the effectiveness of venlafaxine, and three trials 
which were terminated [43], or completed without published outputs or are of unknown status 
[44,45]. A total of 7 studies met the inclusion criteria. Figure 1 shows details of the search 
process.        
Results 
Antidepressants versus placebo  
Three studies compared sertraline with placebo [19,21,46], one RCT compared both sertraline 
and mirtazapine to placebo [47]; imipramine [20], fluoxetine [22] and clomipramine [18] were 
examined in one study each. 
Primary outcome 
Response to treatment (dichotomous outcome) 
Efficacy at 6-13 weeks and 24-39 weeks 
Six studies (involving 520 patients) contributed data on short-term response [18,19,21,22,46,47]. 
There was no statistically significant difference on odds of response between antidepressants and 
placebo (OR 1.95, 95% confidence interval (CI) 0.97 to 3.92, p = 0.06) (see Figure 2). There was 
significant heterogeneity between studies (I² = 61%). Only two studies (involving 359 patients) 
contributed data on long-term response [46,47]. The odds of response did not differ between 
antidepressants and placebo (OR 1.08, 95% CI 0.69 to 1.69, p = 0.74, I² = 8%).  
Mean depression scores (continuous outcome) 
Efficacy at 6-13 weeks and 39 weeks 
There were no statistically significant difference between antidepressants and placebo, with a 
standardised mean difference (SMD) of -0.13 (95% CI -0.49 to 0.24), five studies, 311 
participants) (see Figure 3), with moderate heterogeneity between studies (I² = 50%) [19-22,47]. 
8 
 
Only one study [47] contributed data on long-term response for mean depressive symptoms; 
mean difference (MD) of -0.00 (95% CI -1.77 to 1.77, 1 study, 150 participants).            
Secondary outcomes 
Cognition (MMSE scores) (continuous outcome)    
Efficacy 6-13 weeks 
Five studies [18-20,22,47] provided data for this outcome, showing no statistically significant 
difference between antidepressants and placebo, with a mean difference (MD) of 0.14 (95% CI -
1.65 to 1.93, 251 participants, I² = 0%, Figure 4).    
Acceptability: number of drop-outs (dichotomous outcome) 
Efficacy 6-13 weeks and 24-39 weeks  
At 6-13 weeks, similar numbers of patients dropped out of the intervention and control groups 
(OR 1.40, 95% CI 0.88 to 2.23, p = 0.15; seven studies, 523 participants, I² = 0%, Figure 5), with 
all studies contributing to the analyses [18-22,46,47]. Data from two studies [46,47] showed that 
there were no differences between the two groups on number of drop-outs for long-term response 
(OR 1.31, 95% CI 0.81 to 2.13, p = 0.27; 347 participants, I² = 15%).            
Tolerability: number of adverse events (dichotomous outcome) 
Efficacy 6-13 weeks and 39 weeks 
Although more adverse events were reported by patients in the intervention group, there were no 
significant differences overall between the two groups (OR 1.91, 95% CI 0.92 to 3.96, p = 0.08; 
seven studies; [18-22,46,47] 632 patients, I² = 0%, Figure 6). One trial [47] contributed data on 
adverse events long-term (OR 1.30, 95% CI 0.67 to 2.54, p = 0.44; 326 participants), with no 
differences between the two groups.         
Risk of bias and overall quality of evidence  
9 
 
Figure 7 shows authors' judgements about each risk of bias item presented as percentages across 
all included studies. As can be seen from the graph, bias was detected predominantly in the 
domains of sequence generation and blinding of outcome, limitations applicable to earlier 
studies. Using the GRADE approach, the overall quality of evidence was judged as moderate 
indicative of a possibility that a new trial added to the meta-analysis could change the estimate of 
the effect (see Appendix Figure 8).      
Discussion 
      We found that the overall evidence of effectiveness for antidepressants in people with AD is 
small, with only a few clinical trials conducted to date. Our pooled meta-analysis (6 RCTs, 297 
patients treated with antidepressants and 223 with placebo) failed to show significant differences 
between antidepressants and placebo for response to treatment. Although the overall difference 
between antidepressants and placebo failed to reach accepted levels of statistical significance, the 
analysis trended towards treatment response (p=0.06), with the smaller trials contributing a 
positive effect of antidepressants. Although our overall analyses were negative, we cannot fully 
rule out a possible clinical advantage of antidepressants because of the paucity of RCTs. As most 
studies to date except for the Banerjee et al., (2011) trial have been small, we conclude that 
further research is required to definitively confirm or refute effectiveness.   
     Data from five studies from 311 participants (147 treated with antidepressants and 164 with 
placebo) showed that antidepressants were not superior to placebo in terms of depressive 
symptoms. For continuous scores, the majority of studies used the Hamilton Depression Rating 
Scale for Depression (HRSD) [38] which has not been validated for use in patients with 
Alzheimer’s disease, whilst the remaining studies used the Cornell Scale for Depression in 
Dementia (CSDD) [40]. No research evidence or consensus exists as to what constitutes a 
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clinically meaningful difference in depressive symptoms between drug and placebo treatment in 
AD. The National Institute for Health and Clinical Excellence requires a difference of at least 
three points as a criterion for clinically significant change in depression in the general population 
[48].   
     When we examined other outcomes we found no significant differences in drop-out between 
antidepressants and placebo, and no differences in effect on cognition. For tolerability, although 
more adverse events were reported in the antidepressant group, there were no significant 
differences.  
     Risk of bias analyses showed that although all included studies were double blind RCTs, there 
was evidence of unclear risk in some domains, mostly within the earlier studies. Based on the 
GRADE system, we were able to classify the overall quality of evidence as 'moderate' for both 
treatment response and depressive symptoms, because of methodological limitations and the 
limited number of trials.  
     This review followed guidelines set out by the Cochrane Collaboration [49]. We used a 
comprehensive and sensitive strategy to identify all RCTs reported in the literature, and selection 
of studies, data extraction, and assessments of risk of bias were independently conducted by two 
authors. However, there are limitations to our review. Identified RCTs were heterogeneous with 
regards to participants selected and the type of treatments involved, as the class of antidepressant 
differed and in two of the trials not all participants had major depression. Duration of exposure to 
antidepressants also differed and the majority of RCTs contributing data to the meta-analysis had 
fewer than 50 participants. It was not possible to test for publication bias which may have 
influenced the results.        
      Implications for practice and research 
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      The small number of studies and the variations in terms of type of antidepressant tested make 
it difficult to draw conclusions about the effectiveness of pharmacological treatments for 
depression in people with AD. There is a need for further well-designed multicentre RCTs which 
adhere to high standards of methodology and reporting and include diagnostically homogenous 
populations and large samples. The lack of evidence base makes it difficult to use this research to 
inform evidence-based policy about whether antidepressants are effective in treating depression 
in people with Alzheimer’s disease.  
     Interaction effects may have contributed to the results of this review such as type of 
antidepressant, dose and severity of depressive symptoms and should be investigated in future 
research. Results of our review suggest that the pathophysiology of depression in AD may be 
different to that of primary depression, as indicated by lack of evidence of pathological changes 
in monoaminergic nuclei in people with AD [50,51], and may therefore explain lack of efficacy 
of conventional antidepressant treatments. An alternative hypothesis to underlying deficits in 
monoamine neurotransmitters includes deficits in glutamatergic transmission, which has led to a 
call for further research in identifying biomarkers and treatments for depression in AD that 
extent beyond the monoaminergic hypothesis [52].            
     Despite the limited and contradictory evidence regarding efficacy of antidepressants in AD, 
they are still commonly prescribed. David et al., (2016) reported a significant increase in 
prescribing rates from 26% in 2010 to 31% in 2014 [53], and similar rates have been seen in 
other studies [54,55]. It is possible that attempts to reduce use of antipsychotics in people with 
dementia have contributed to this. Given evidence that apathy is a co-morbid factor of depression 
in AD [56], associated with different outcomes, it will be important for future studies to report 
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whether people with clinically significant symptoms of apathy are excluded from antidepressants 
trials research.    
     To conclude, this is an up-to-date, methodologically rigorous meta-analysis on the efficacy of 
antidepressants for depression in patients with AD including all available trials. We found no 
clear evidence to support the efficacy of antidepressants for treating depression in AD. These 
findings do not mean that people with severe depression and AD should not be treated with 
antidepressants. Given this review is limited by a paucity of trials, small studies overall and 
variation in patients recruited, further RCTs are needed to confirm the effects of antidepressants 
in AD.  
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Figure 1: Flow diagram of the review 
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Figure 2. Forest plot of comparison of antidepressants versus placebo: Response to treatment (6-
13 weeks)    
 
 
 
Figure 3. Forest plot of comparison of antidepressants versus placebo: Mean depression scores 
(6-13 weeks)    
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Figure 4. Forest plot of comparison of antidepressants versus placebo: Cognition MMSE scores 
(6-13 weeks)    
 
 
Figure 5. Forest plot of comparison of antidepressants versus placebo: Acceptability Number of 
drop-outs (6-13 weeks)   
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Figure 6. Forest plot of comparison of antidepressants versus placebo: Tolerability Number of 
adverse events (6-13 weeks)    
 
 
 
 
 
Figure 7. Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies. 
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Appendix 1 Supplementary file 
 
Search strategy 
1. Alzheimer*.mp.  
 
2. AD.mp.  
 
3. exp Alzheimer Disease/ 
 
4. Dement*.mp.  
 
5. exp Dementia/ 
 
6. exp Dementia/ 
 
7. anti-depres*.mp.  
 
8. antidepres*.mp.  
 
9. exp Antidepressive Agents/ 
 
10. citalopram.mp.  
 
11. exp Citalopram/ 
 
12. escitalopram.mp.  
 
13. paroxetine.mp.  
 
14. exp Paroxetine/ 
 
15. fluoxetine.mp.  
 
16. exp Fluoxetine/ 
 
17. fluvoxamine.mp.  
 
18. exp Fluvoxamine/ 
 
19. trazodone.mp.  
 
20. exp Trazodone/ 
 
21. nefazodone.mp.  
 
22. venlafaxine.mp.  
 
23. duloxetine.mp.  
 
24. reboxetine.mp.  
 
25. bupropion.mp.  
 
26. exp Bupropion/ 
 
27. amoxapine.mp.  
 
28. exp Amoxapine/ 
 
29. amitriptyline.mp.  
 
30. exp Amitriptyline/ 
 
31. nortriptyline.mp.  
 
32. exp Nortriptyline/ 
 
33. desipramine.mp.  
 
34. exp Desipramine/ 
 
35. trimipramine.mp.  
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36. exp Trimipramine/ 
 
37. imipramine.mp.  
 
38. exp Imipramine/ 
 
39. protriptyline.mp.  
 
40. exp Protriptyline/ 
 
41. doxepin.mp.  
 
42. exp Doxepin/ 
 
43. clomipramine.mp.  
 
44. exp Clomipramine/ 
 
45. mirtazapine.mp.  
 
46. mianserin.mp.  
 
47. exp Mianserin/ 
 
48. moclobemide.mp.  
 
49. exp Moclobemide/ 
 
50. phenelzine.mp.  
 
51. exp Phenelzine/ 
 
52. tranylcypromine.mp.  
 
53. exp Tranylcypromine/ 
 
54. SSRI*.mp.  
 
55. selective serotonin reuptake inhibitor.mp.  
 
56. TCA*.mp.  
 
57. depress*.mp.  
 
58. dysthymi*.mp.  
 
59. adjustment disorder*.mp.  
 
60. mood disorder*.mp.  
 
61. affective disorder.mp.  
 
62. affective symptom*.mp.  
 
63. exp Depression/ 
 
64. exp Depressive Disorder, Major/ 
 
65. exp Depressive Disorder/ 
 
66. exp Dysthymic Disorder/ 
 
67. exp Alzheimer Disease/ or exp Dementia/ 
 
68. (behavioural and psychological symptoms of dementia).mp.  
 
69. neuropsychiatric symptom*.mp.  
 
70. NPS.mp.  
 
71. exp Behavioral Symptoms/ 
 
72. exp Psychomotor Agitation/ 
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73. randomized controlled trial.pt. 
 
74. controlled clinical trial.pt. 
 
75. randomized.ab. 
 
76. randomised controlled trial.tw. 
 
77. placebo.ab. 
 
78. random*.ab. 
 
79. drug therapy.fs. 
 
80. randomly.ab. 
 
81. trial.ab. 
 
82. 1 or 2 or 3 or 4 or 5 or 6 
 
83. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 
25 or 26 or 27 or 28 or 29 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 
45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 
 
84. 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 
 
85. 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 
 
86. 82 and 83 and 84 and 85 
 
87. limit 86 to humans 
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Table 1 Characteristics of Excluded Studies 
 
1 
 
Rozzini 2010 
 
Not a RCT, observational study on the use of SSRIs on cognition in patients 
with AD of which some were depressed 
2 Mowla 2007 Double-blind placebo-controlled RCT of fluoxetine in mild to moderate AD,  
patients with major or minor depression were excluded  
3 de Vasconcelos 2007 Double-blind placebo-controlled RCT study of venlafaxine for depression in 
dementia, no separate data available for patients with AD 
4 Rao 2006 Not a RCT, open label treatment study of escitalopram for depression in AD 
5 Finkel 2004 Double-blind placebo-controlled RCT on efficacy of sertraline in people with 
AD and behavioural disturbances, patients with AD were not depressed and 
those with psychiatric disorders were excluded 
6 Oslin 2003 
 
Double blind controlled trial of venlafaxine versus sertraline in depressed 
nursing home residents, no placebo arm or separate data for patients with AD 
7 Moretti 2002 Study on efficacy of SSRIs in patients with AD, randomisation unclear. 
Patients with AD were not depressed and those with psychiatric disorders 
were excluded 
8 Lanctot 2002 Double-blind placebo-controlled cross-over RCT of sertraline in 
nondepressed patients with severe probable AD and behavioural 
disturbances, those with major depression were excluded 
9 Raji 2001 Not a RCT, report on three case studies on the use of mirtazapine in the 
treatment of depression in AD 
10 Streim 2000 Double-blind RCT of nortriptyline in nursing home residents with depression 
(of which some had dementia), no placebo arm and no separate data available 
for patients with AD   
11 Karlsson 2000 Double-blind RCT on efficacy of citalopram compared to mianserin in 
depressed patients with or without dementia, no placebo arm and no separate 
data for patients with AD   
12 Katona 1998 Double-blind RCT comparing paroxetine with imipramine in depressed 
patents with dementia, no placebo arm and no separate data for patients with 
AD   
13 Trappler 1998 
 
Not a RCT, open label trial on use of SSRIs (fluoxetine, sertraline, and 
paroxetine) in depressed nursing home residents of which some had AD 
14 Pfeiffer 1997 Not a RCT, open label study on use of venlafaxine in depressed patients with 
AD 
15 Taragano 1997 Double-blind RCT of fluoxetine vs. amitriptyline in the treatment of major 
depression in AD, no placebo arm 
16 Roth 1996 Double-blind placebo-controlled RCT of moclobemide in older people with 
dementia and/or depression, no separate data available for patients with AD   
17 Volicer 1994 
 
Not a RCT, report on case studies on use of sertraline in people with 
advanced AD and depression 
18 Fuchs 1993 Double-blind placebo-controlled RCT of the effect of maprotiline in patients 
with dementia and mild depression, no separate data for patients with AD, 
excluded patients in need of antidepressant therapy 
19 Passeri 1993 Double-blind RCT of 5’-methlytetrahydrofolic acid (5'-MTHF) vs trazodone 
on depressive symptoms in normofolatemic older people with mild to 
moderate dementia and depression, no placebo arm or separate data for 
patients with AD   
20 Nyth 1992 Double-blind placebo-controlled RCT of citalopram in depressed older 
people and/or dementia, no separate data available for patients with AD   
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21 Haupt 1991 Not a RCT, report on a case study on use of mianserine for treating 
depression in Alzheimer's Disease  
22 Lawlor 1991 Double-blind placebo-controlled RCT crossover trial of meta-
chlorophenylpiperasine in patients with moderate to severe AD, behavioural 
disturbances and levels of mild depression, patients did not meet criteria for 
major depression 
23 Reynolds 1987 
 
Not a RCT, open trial of nortriptyline in older people with depression and/or 
dementia, no separate data available for patients with AD   
24 Jenike 1985  Not a RCT, report on case studies on use of standard antidepressants and 
monoamine oxidase inhibitors in depressed patients with AD 
25 Mokhber 2014 
 
Double-blind  RCT of sertraline, venlafaxine, and desipramine in depressed 
patients with moderate AD, no placebo arm 
26 Passeri 1987 
 
Double-blind placebo-controlled RCT of minaprine in patients with AD and 
multi-infarct dementia (MID), patients were not depressed and those with a 
psychiatric illness were excluded   
27 Mizukami 2006 Not a RCT, open label trial of milnacipran in treating depression in AD 
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Antidepressants compared to placebo for depression in Alzheimer's disease 
Patient or population: Depression in Alzheimer's disease  
Setting: Community and nursing home care  
Intervention: Antidepressants  
Comparison: Placebo 
Outcome 
№ of participants 
(studies)  
Relative 
effect 
(95% 
CI)  
Anticipated absolute effects (95% CI)  Quality  
Without 
Antidepressants 
With 
Antidepressants 
Difference 
Treatment response assessed with: Depression rating scale 
or clinician-rated global impression of change scale 
Follow up: range 6 to 13 weeks 
№ of participants: 520 
(6 RCTs)  
OR 
1.95 
(0.97 to 
3.92)  
42.2%  58.7% 
(41.4 to 74.1)  
16.5% 
more 
(0.7 fewer 
to 31.9 
more)  
⨁⨁⨁
◯ 
MODERATE 
1 
 
Mean Depression scores  
assessed with: Depression Rating Scales (Cornell Scale for 
Depression in Dementia – CSDD or Hamilton Depression 
Rating Scale –HAM-D) 
Follow up: range 6 to 13 weeks 
№ of participants: 311 
(5 RCTs)  
-  -  -  SMD 0.13 
fewer 
(0.49 
fewer to 
0.24 
more)  
⨁⨁⨁
◯ 
MODERATE 
1 
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
 
CI: Confidence interval; OR: Odds ratio; SMD: Standardised mean difference  
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility 
that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
1. Studies included few participants and events and evidence of inconsistency in whether there was an effect 
Figure 8: Summary of findings table: antidepressants versus placebo for depression in Alzheimer’s 
disease  
